Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

 Kimberley Tam

Kimberley Tam

MIT Alliance for Research and Technology, Singapore

Title: Mesenchymal stromal cell (MSC) derived osteoprogenitors for the treatment of degenerative disc disease (DDD)

Biography

Biography: Kimberley Tam

Abstract

Abstract

Introduction: MSCs are easily procured from bone marrow (BM) aspirates and may be suitable for adapting successfully to the environment of the intervertebral disc (IVD) to stimulate regeneration. Through novel technology for identifying and biophysically sorting MSC subpopulations, we demonstrate that implantation of MSC derived osteoprogenitors leads to the greatest efficacy in restoring IVD matrix and function in murine models.

Methods: We studied various biophysical traits of MSCs and created microfluidic sorters that isolate an osteoprogenitor subpopulation for clinical use. IVD cells were obtained from 5 patients for analysis (L3/4, L4/5, L5/S1). We correlated pain scores with gene expression of IVD cell-produced proteins to identify biomarkers relevant to DDD. We also evaluated pre-clinically the efficacy of different MSC subpopulations in reversing degeneration in IVD cells both in vitro and in vivo.

Results: MSC osteoprogenitors are defined biophysically from other subpopulations as cells with >20μm diameter, >375Pa stiffness and <1.2% nuclear fluctuation; functionally, MSC osteoprogenitors differentiate most readily into osteo/chondro-lineages and also secrete more Aggrecan, Fgf1, Ang-1, etc, making them potentially optimal for stimulating regeneration of both IVD cells and matrix. qPCR studies of patient IVD cells show a>5 fold Aggrecan decrease with a corresponding 3 point pain increase (scale of 0-10). Stimulation of patient IVD cells with osteoprogenitors in vitro greatly restored production of Aggrecan (~2.5 fold improvements compared to other MSC subpopulations). Protein expression of ANG-1 was also significantly higher when IVD cells were treated with MSC osteoprogenitors in vitro. In murine models, the administration of osteoprogenitors most potently restored the decrease in original disc height after injury using MRI and histopathological scoring system.

Conclusion: We demonstrate a facile and clinically relevant strategy for deriving an MSC osteoprogenitor subpopulation for cell-therapy in DDD, which may potentially be more efficacious in reversing the underlying degeneration in the IVD.